MiR ‐375 in CAFs ‐Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC
Cancer Science · 2026-08 · 117 (8) · 2208-2220
DOI: 10.1111/cas.70422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 24.05.2026. Verfasst von Wei Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China. Hauptthemen laut MEDLINE: MicroRNAs, Liver Neoplasms, Carcinoma, Hepatocellular, Extracellular Vesicles. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Fundamental Research Program, Guangdong Basic and Applied Basic Research Foundation, Medical Scientific Research Foundation of Guangzhou City.
Abstract (Originalsprache)
Cancer‐associated fibroblasts (CAFs) in the tumor microenvironment play an important role in cancer initiation and progression through mediating crosstalk between CAFs and cancer cells. In our study, we unveiled that CAFs‐derived extracellular vesicles (EVs) could deliver miR‐375 to endothelial cells (EC) and further contribute to tumor angiogenesis by regulating Ras GTPase Activating Protein 1 (RASA1) in hepatocellular carcinoma (HCC). We also found that HCC patients with more advanced disease showed higher levels of miR‐375 in plasma EVs, which were preferentially expressed in the EVs of CAFs. These data provided direct evidence supporting the pivotal role of the tumor suppressor miR‐375, which is selectively sorted into CAF‐derived EVs, in promoting angiogenesis during HCC progression and revealed that genetically modified CAF‐derived EVs may provide a potential therapeutic strategy for HCC. Furthermore, our study indicated that miR‐375 in plasma EVs could serve as a potential predictive and prognostic biomarker in HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
- Department of Hepatic Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Pancreatic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Anesthesiology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Department of Breast Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Wei Qin
Förderung
- Shenzhen Fundamental Research Program
- Guangdong Basic and Applied Basic Research Foundation
- Medical Scientific Research Foundation of Guangzhou City
- Shanghai Sailing Program
- National Natural Science Foundation of China
- Shenzhen Municipal Fundamental Research Program
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Qin, W., Wang, L., Hu, B., Xiao, C., Wu, X., Tian, H., & Peng, S. (2026). MiR ‐375 in CAFs ‐Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC. Cancer Science, 117(8), 2208-2220. https://doi.org/10.1111/cas.70422
Vancouver
Qin W, Wang L, Hu B, Xiao C, Wu X, Tian H, et al. MiR ‐375 in CAFs ‐Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC. Cancer Science. 2026;117(8):2208-2220. doi:10.1111/cas.70422
BibTeX
@article{Qin2026,
author = {Qin, Wei and Wang, Li and Hu, Beiyuan and Xiao, Cuicui and Wu, XiaoYing and Tian, Huan and Peng, Songlin},
title = {MiR ‐375 in CAFs ‐Derived EVs Promotes HCC Progression via Regulating RASA1 and May Potentially Serve as a Biomarker for HCC},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {8},
pages = {2208--2220},
doi = {10.1111/cas.70422}
}
EUVIMED